JAK inhibitors for children with alopecia areata
Treatments studied
Part of Skin clinical trials.
This study looks at how well JAK inhibitor pills work for children with alopecia areata (a condition that causes hair loss). If you have tried one of these medicines for at least 3 months, your experience could help doctors learn more about the best treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 2 and 18 years old.
- You have been diagnosed with alopecia areata (patchy hair loss).
- You have taken a JAK inhibitor pill (such as tofacitinib, baricitinib, ritlecitinib, abrocitinib, upadacitinib, or ifidancitinib) for more than 3 months.
- You have not had hair transplant surgery.
- Your hair loss is not caused by another condition like psoriasis or lichen planus.
- You are not taking part in any other clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a pill called baricitinib for people with active alopecia areata that started within the last 3 months. Baricitinib is a type of medication called a JAK inhibitor, which can help calm the immune system and stop hair loss.
This study tests an oral tablet called upadacitinib for people with severe alopecia areata who have lost at least half of their scalp hair. It aims to see if the drug can safely help hair regrow.
This Phase 2 study tests ruxolitinib to see if it safely helps regrow hair in people whose alopecia areata is linked to APECED (a rare immune condition). You may qualify if you have significant scalp hair loss for at least 6 months and haven’t had regrowth with other treatments.
This study tests if the medicine ritlecitinib can help regrow hair in people with alopecia areata, a condition that causes patchy hair loss. It's for young people and adults who have lost between 20% and 50% of their scalp hair for at least 6 months but no more than 10 years.
This trial compares two medications, tofacitinib and methotrexate, to see which works better for severe hair loss caused by alopecia areata. If you have severe alopecia areata (total or universal hair loss), this study may offer a chance to try a new treatment option.
This study follows people with alopecia areata who are starting treatment with ritlecitinib (a medication). It looks at how well the treatment works in real life and how it affects your symptoms and quality of life.
Hear when a new Alopecia Areata trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.